ELDN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ELDN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Eledon Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eledon Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Eledon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Eledon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Eledon Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Eledon Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:
For example, Eledon Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -0.34 | / | 131.7762 | * | 131.7762 | |
= | -0.340 |
Current CPI (Mar. 2024) = 131.7762.
Eledon Pharmaceuticals Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201406 | -45.654 | 100.560 | -59.826 |
201409 | -48.775 | 100.428 | -64.000 |
201412 | -45.360 | 99.070 | -60.335 |
201503 | -95.579 | 99.621 | -126.429 |
201506 | -64.800 | 100.684 | -84.811 |
201509 | -85.859 | 100.392 | -112.701 |
201512 | -79.379 | 99.792 | -104.820 |
201603 | -82.619 | 100.470 | -108.362 |
201606 | -1.350 | 101.688 | -1.749 |
201609 | -2.610 | 101.861 | -3.377 |
201612 | -1.596 | 101.863 | -2.065 |
201703 | -1.180 | 102.862 | -1.512 |
201706 | -23.760 | 103.349 | -30.295 |
201709 | -7.740 | 104.136 | -9.794 |
201712 | -11.260 | 104.011 | -14.266 |
201803 | -6.480 | 105.290 | -8.110 |
201806 | -6.120 | 106.317 | -7.586 |
201809 | -6.660 | 106.507 | -8.240 |
201812 | -8.820 | 105.998 | -10.965 |
201903 | -9.360 | 107.251 | -11.500 |
201906 | -6.300 | 108.070 | -7.682 |
201909 | -4.010 | 108.329 | -4.878 |
201912 | -5.680 | 108.420 | -6.904 |
202003 | -8.520 | 108.902 | -10.310 |
202006 | -2.740 | 108.767 | -3.320 |
202009 | -5.510 | 109.815 | -6.612 |
202012 | -0.389 | 109.897 | -0.466 |
202103 | -0.570 | 111.754 | -0.672 |
202106 | -0.500 | 114.631 | -0.575 |
202109 | -0.660 | 115.734 | -0.751 |
202112 | -0.600 | 117.630 | -0.672 |
202203 | -0.690 | 121.301 | -0.750 |
202206 | -0.650 | 125.017 | -0.685 |
202209 | -0.730 | 125.227 | -0.768 |
202212 | -4.090 | 125.222 | -4.304 |
202303 | -0.750 | 127.348 | -0.776 |
202306 | -0.400 | 128.729 | -0.409 |
202309 | -0.350 | 129.860 | -0.355 |
202312 | -0.290 | 129.419 | -0.295 |
202403 | -0.340 | 131.776 | -0.340 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Eledon Pharmaceuticals (NAS:ELDN) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Allan Kirk | director | C/O ELEDON PHARMACEUTICALS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Robinson James A. Jr. | director | 852 WINTER STREET, WALTHAM MA 02451 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Steven Perrin | director, officer: See Remarks | C/O ANELIXIS THERAPEUTICS, INC., 1500 DISTRICT AVENUE, BURLINGTON MA 01803 |
David-alexandre C Gros | director, officer: Chief Executive Officer | 220 MARLBOROUGH STREET, #6, BOSTON MA 02116 |
Jan Hillson | director | C/O ELEDON PHARMACEUTICALS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Paul Sean Little | officer: CHIEF FINANCIAL OFFICER | SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117 |
Bryan E. Smith | officer: See Remarks | C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
June Lee | director | C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080 |
Orbimed Israel Biofund Gp Limited Partnership | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
Logos Global Management Lp | 10 percent owner | 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129 |
Bvf Partners L P/il | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Mark N Lampert | 10 percent owner | 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
Biotechnology Value Fund Ii Lp | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By Value_Insider Value_Insider • 11-14-2022
By Marketwired • 10-23-2023
By Marketwired • 09-05-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Value_Insider Value_Insider • 11-03-2022
By PurpleRose PurpleRose • 08-04-2022
By Marketwired • 08-10-2023
By PurpleRose PurpleRose • 07-18-2022
By sperokesalga sperokesalga • 05-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.